Jeff Packman, MBA, is a highly experienced clinical development executive with nearly three decades of international experience in regulatory affairs, manufacturing, clinical operations, and orphan drug development.
Mr. Packman was previously Chief Development Officer of Clementia Pharmaceuticals, where he led the successful execution of the company’s palovarotene drug development program in Fibrodysplasia Ossificans Progressiva (FOP) prior to the company’s acquisition by Ipsen in April 2019. Prior to his role with Clementia, Mr. Packman served as Chief Development Officer for Apofore Corporation, a start-up focused on the development of novel diabetes therapeutics. Prior to Apofore, Mr. Packman was Vice President of Drug Development Operations at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Mr. Packman also headed development operations at Oscient Pharmaceuticals and worldwide business operations for the regulatory affairs division of PAREXEL International Corporation.
Mr. Packman earned a Bachelor of Arts degree in Biology from Colby College and an MBA with Highest Honors from the F. W. Olin Graduate School of Business Administration at Babson College in Massachusetts.